Audio Epilepsy Digest

In the current issue

A Positive Signal With a Negative Primary Endpoint: The NAUTILUS Trial.

This monthly special is a journal-club reading of NAUTILUS, the randomized sham-controlled trial of responsive centromedian thalamic stimulation for drug-resistant idiopathic generalized epilepsy with recurrent generalized tonic-clonic seizures.

The episode's main point is endpoint discipline: the primary safety endpoint was met, the prespecified primary effectiveness endpoint was not statistically significant, and the longer-term and post hoc signals remain clinically important but bounded.

In this issue5 topics

NAUTILUS is an encouraging signal, not a simple positive trial.
The prespecified primary effectiveness endpoint was not statistically significant.
Post hoc and 18-month seizure outcomes matter clinically but cannot erase the endpoint hierarchy.
Centromedian thalamic RNS belongs in careful counseling and referral discussions for selected drug-resistant IGE patients with recurrent GTCS.
The trial does not establish thalamic RNS as standard-of-care therapy for IGE.

AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

Back issues 9 issues

No.09

Monthly_special

From Paper to Podcast: The AED Assembly Line.

This special episode explains how Audio Epilepsy Digest is made. Instead of reviewing new epilepsy papers, it follows the AED assembly line from source selection and episode framing through AI-assisted drafting, transcript review, human editorial judgment, public source-review pages, and listener feedback.
In this discussion · Source packet
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.08

Weekly

Status Epilepticus in Critical Care.

This weekly recent-studies episode uses papers from roughly the last month, plus ESETT as a landmark context study, to ask what happens when status epilepticus moves beyond the emergency algorithm and becomes a critical-care problem.
In this discussion · 5 topics
1. ESETT anchors one second-line convulsive status decision point, but it does not settle ICU/SRSE/NORSE salvage care.
2. ICU status epilepticus care is shaped by systems constraints, especially cEEG access, training, and workflow.
3. Point-of-care AI seizure-burden estimates are associated with discharge outcomes, but do not prove that AI-guided treatment improves outcomes.
4. Perfusion imaging can add diagnostic context in selected seizure-vs-stroke-mimic or IIC situations, but EEG remains central.
5. VNS and emergency resection are salvage conversations, not routine generalized pathways.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.07

Weekly

Real-World Evidence Meets Surgical Assumptions.

This weekly recent-studies episode uses papers published in roughly the last month to ask how epileptologists should counsel patients with drug-resistant focal epilepsy when new evidence strengthens some assumptions, weakens others, and warns against turning plausible anatomy or AI output into shortcuts.
In this discussion · 4 topics
1. RNS postapproval data strengthen confidence in long-term palliative neuromodulation for selected adults with focal epilepsy, but they do not define universal treatment sequencing.
2. PMG-related epilepsy can be surgically treatable in selected patients, but the visible malformation is not automatically the full epileptogenic zone.
3. A 2026 validation study found no association between connectivity-defined piriform cortex resection and seizure freedom, arguing against routine targeting while preserving patient-specific network evaluation.
4. LLMs can organize seizure-semiology information above chance in a benchmark task, but reasoning and citation errors keep them in the decision-support category.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.06

Monthly_special

From Random Seizures to Risk States.

Episode 6 examines seizure timing, epilepsy chronobiology, and seizure forecasting.
In this discussion · 4 topics
1. Seizure timing can reflect circadian, sleep-wake, sleep-drive, and multidien risk rhythms, but that does not mean seizures are reliably predictable in routine care.
2. Forecasting claims need past-only implementation, meaningful chance models, simple benchmarks, prospective validation, and attention to false alarms and patient burden.
3. Wearable, diary, and home EEG studies show why the field is plausible, but feasibility and proof of principle are not the same as clinical effectiveness.
4. Medication-timing models and sleep-drive experiments are useful for hypothesis generation, not patient-specific treatment advice.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.05

Weekly

Cognition Is Becoming Actionable.

Episode 5 asks whether epilepsy cognition is moving from passive comorbidity to measurable, partly modifiable care target.
In this discussion · 4 topics
1. Tai et al. link self-reported sleep duration with executive function and dementia-risk signal in focal epilepsy, but this remains observational and hypothesis-generating.
2. The IC-CoDE Portal lowers the barrier to reproducible cognitive phenotyping for research cohorts, but it is not a clinical decision tool.
3. The rehabilitation trial supports improved patient-reported quality of life and anxiety more strongly than objective memory improvement.
4. Zelano et al. show survival associations by first ASM in dementia plus epilepsy, but registry data cannot causally rank medications.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.04

Weekly

Drug-Resistant Epilepsy in 2026.

Does the pathway after two failed antiseizure medications still end in surgery?
In this discussion · 4 topics
1. Pellinen's cenobamate findings support a single-center association with delayed or deferred surgery in selected patients, not causal proof that cenobamate replaces surgery.
2. Kerr and McFarlane frame the essential distinction: surgical delay is not the same as surgical obviation.
3. FRANCE suggests potential benefit for ANT-DBS in a highly refractory VNS-failed cohort, but it did not statistically prove superiority over best medical therapy.
4. Aiello's ANT spectral biomarkers are promising and hypothesis-generating, but they are not validated responder-prediction or programming rules.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.03

Weekly

Epilepsy Care Beyond the Seizure Count.

What should epilepsy care measure when seizure counts are not enough?
In this discussion · 4 topics
1. Respiratory physiology may become an important risk-signal domain, but the current respiratory-variability study should not be heard as a validated individual SUDEP prediction tool.
2. At-home EEG self-monitoring appears feasible for selected, supported patients, but it does not replace routine EEG, ambulatory EEG, EMU evaluation, or expert interpretation.
3. Patient-facing definitions of ictal impairment of consciousness can be understandable, but terminology comprehension is not the same as proof of improved clinical outcomes.
4. Patient-burden research reinforces that seizure counts miss mood symptoms, fatigue, sleep disruption, productivity effects, and caregiver burden, while the current survey remains selected and descriptive.
AI source review / Listen on Spotify / Apple Podcasts / Amazon Music
No.02

Weekly

What Seizure Counts Miss.

What changes in epilepsy care when we widen the lens beyond raw seizure counts?
In this discussion · 4 topics
1. Pediatric status epilepticus should trigger earlier and more systematic thinking about genetic evaluation, especially in younger children and mixed focal-generalized phenotypes.
2. The accelerated long-term forgetting signal in newly diagnosed focal epilepsy is task-specific: story memory and verbal recognition look more vulnerable than a blanket all-domain memory model would suggest.
3. Dose escalation in generalized epilepsy should remain drug-specific rather than assumed to be monotonic across all ASMs, with the strongest practical caution in this cohort applying to lamotrigine doses above the moderate range.
4. Rescue-medication effectiveness may be better captured by seizure-interval change than by endpoints borrowed from chronic maintenance treatment, but the current SEIVAL paper is best heard as endpoint-development work rather than practice-changing efficacy proof.
Show notes & references / Listen on Spotify / Apple Podcasts / Amazon Music
No.01

Special

Special Episode: Thalamic sEEG, Standard of Care or Research?

Should thalamic sEEG sampling be standard of care, selectively hypothesis-driven, or research-only?
In this discussion · 4 topics
1. The strongest argument for restraint is not that thalamic recordings are never interesting, but that incremental patient-level clinical benefit remains uncertain in many cases and may not justify routine added sampling.
2. The strongest argument for selective clinical use is that thalamic signals can become decision-relevant when the pre-implant hypothesis already involves network propagation, neuromodulation targeting, or uncertainty that cortical-only sampling may not resolve.
3. The pro-neuromodulation position is more intervention-oriented than the stricter research-only framing and treats thalamic sampling as part of a therapeutic planning workflow, not only a localization experiment.
4. Much of the packet is interpretation and expert argument rather than direct comparative outcomes evidence, so this should be heard as a policy and practice debate, not a settled consensus statement.
Show notes & references / Listen on Spotify / Apple Podcasts / Amazon Music

About the publication

Audio Epilepsy Digest turns recent epilepsy research into a single weekly audio brief for epileptologists, epilepsy fellows, and surgical epilepsy teams. Episodes favor primary and authoritative sources, prefer full-text synthesis over abstract skimming, and stay explicit about the distinction between what a study supports and what it does not.

The show is an evolving collaboration between a human editor and AI co-hosts. Audio may misinterpret or oversimplify source material; the original published articles remain the authoritative reference for clinical decision-making. Corrections and feedback are welcome and directly shape future issues.